RAD202

RAD202 is a proprietary single-domain antibody (nanobody) radiopharmaceutical developed for the treatment of HER2-expressing solid tumors. It specifically targets the Human Epidermal growth factor Receptor 2 (HER2), which is overexpressed in breast cancer and several other solid tumors. The drug is designed as a therapeutic radiopharmaceutical by conjugating the nanobody to radioisotopes such as Lutetium-177 (for therapy) or Technetium-99m/Gallium-68 (for imaging). This enables targeted delivery of ionizing radiation to tumor cells while minimizing exposure to healthy tissue. Preclinical and early clinical data have demonstrated favorable biodistribution, high tumor uptake, significant inhibition of tumor growth in HER2-positive xenograft models, and prolonged survival with fractionated dosing regimens. A Phase 1 first-in-human trial evaluating safety and preliminary efficacy in advanced HER2-positive cancers is ongoing[1][4][5][6][7].

Other names

Lu-177 RAD202Lu177 RAD202Lu 177 RAD202